有效载荷(计算)
连接器
生物结合
耐受性
计算机科学
抗体-药物偶联物
纳米技术
医学
药理学
单克隆抗体
材料科学
免疫学
抗体
不利影响
网络数据包
操作系统
计算机网络
作者
Mahendra P. Deonarain,Gökhan Yahioglu
标识
DOI:10.1080/17460441.2021.1858050
摘要
Introduction: Antibody-Drug Conjugates (ADCs) have undergone a recent resurgence with 5 product approvals over the last 2 years but for those close to the field, it's been repeated cycles of setbacks and new innovations. A new wave of innovation is in the type of format used to deliver the cytotoxic payloads, with smaller bio-molecules being designed to have more optimal penetration and elimination properties tailored for solid tumors.Areas covered: In this review, the authors cover many of the recently described smaller-format drug conjugates (including formats such as diabodies, Fabs, scFvs, domain antibodies) with an emphasis on the types of conjugation technologies used to attach the chemical linker-payload.Expert opinion: Smaller formats are highly influenced by the structure of the linker-payload, arguably more-so than larger ADCs, so careful consideration is needed where solublising and pharmacokinetic modulation is required. High-quality conjugates are being developed with in vivo tumor efficacy and tolerability properties competitive with ADCs and with a few formats already in clinical development, we expect the pipeline to expand and to reach the market.
科研通智能强力驱动
Strongly Powered by AbleSci AI